JCI vs PCRX · P/E 44, rev $23.60B vs P/E 174, rev $369.8M
Johnson Controls International PLC (JCI) versus Pacira BioSciences, Inc. (PCRX) — a side-by-side from cached financials, not a winner call.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
JCI currently screens at market cap $87.62B and trailing P/E 43.9. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the JCI and PCRX stock pages for the full models.
Not investment advice.